routine B12 level monitoring is generally unnecessary once replacement is established, as levels do not reliably correlate with tissue stores Important safety considerations: Older adults may have impaired renal function, though this rarely affects B12 therapy given its wide safety margin
oral NMN/NR rely on cellular conversion
Staying at each dose level for 6 weeks instead of 4 reduces side effects for sensitive individuals
Because large studies did not show robust, reproducible weightloss outcomes, development as a formal obesity drug was discontinued, and AOD9604 today is typically used offlabel as a wellness or bodycomposition adjunct rather than an FDAapproved obesity medication
For vendor evaluation beyond just water, read best peptide vendors
Before assuming the medication has stopped working, audit the basics